Drugs to Minimize Perioperative Blood Loss in Cardiac Surgery
- 1 December 1997
- journal article
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 85 (6) , 1258-1267
- https://doi.org/10.1213/00000539-199712000-00014
Abstract
Concern about the side effects of allogeneic red blood cell transfusion has increased interest in methods of minimizing perioperative transfusion.We performed meta-analyses of randomized trials evaluating the efficacy and safety of aprotinin, desmopressin, tranexamic acid, and epsilon-aminocaproic acid in cardiac surgery. All identified randomized trials in cardiac surgery were included in the meta-analyses. The primary outcome was the proportion of patients who received at least one perioperative allogeneic red cell transfusion. Sixty studies were included in the meta-analyses. The largest number of patients (5808) was available for the meta-analysis of aprotinin, which significantly decreased exposure to allogeneic blood (odds ratio [OR] 0.31, 95% confidence interval [CI] 0.25-0.39; P < 0.0001). The efficacy of aprotinin was not significantly different regardless of the type of surgery (primary or reoperation), aspirin use, or reported transfusion threshold. The use of aprotinin was associated with a significant decrease in the need for reoperation because of bleeding (OR 0.44, 95% CI 0.27-0.73; P = 0.001). Desmopressin was not effective, with an OR of 0.98 (95% CI 0.64-1.50; P = 0.92). Tranexamic acid significantly decreased the proportion of patients transfused (OR 0.50, 95% CI 0.34-0.76; P = 0.0009). epsilon-Aminocaproic acid did not have a statistically significant effect on the proportion of patients transfused (OR 0.20, 95% CI 0.04-1.12; P = 0.07). There were not enough patients to exclude a small but clinically important increase in myocardial infarction or other side effects for any of the medications. We conclude that aprotinin and tranexamic acid, but not desmopressin, decrease the number of patients exposed to perioperative allogeneic transfusions in association with cardiac surgery. Implications: Aprotinin, desmopressin, tranexamic acid, and epsilon-aminocaproic acid are used in cardiac surgery in an attempt to decrease the proportion of patients requiring blood transfusion. This meta-analysis of all published randomized trials provides a good estimate of the efficacy of these medications and is useful in guiding clinical practice. We conclude that aprotinin and tranexamic acid, but not desmopressin, decrease the exposure of patients to allogeneic blood transfusion perioperatively in relationship to cardiac surgery. (Anesth Analg 1997;85:1258-67)Keywords
This publication has 59 references indexed in Scilit:
- Aprotinin for Primary Coronary Artery Bypass Grafting: A Multicenter Trial of Three Dose RegimensThe Annals of Thoracic Surgery, 1996
- Tranexamic acid use during coronary artery bypass graftingThe Annals of Thoracic Surgery, 1996
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trialsJAMA, 1995
- Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleedingThe Annals of Thoracic Surgery, 1994
- Aprotinin for coronary bypass operations: Efficacy, safety, and influence on early saphenous vein graft patencyThe Journal of Thoracic and Cardiovascular Surgery, 1994
- Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularizationEuropean Journal of Cardio-Thoracic Surgery, 1994
- Blood conservation in cardiac surgeryThe Annals of Thoracic Surgery, 1990
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987
- Bias in Treatment Assignment in Controlled Clinical TrialsNew England Journal of Medicine, 1983